Search Results | Blood | American Society of Hematology

1-20 of 70

2 3 4

Sort by

Sort Order Select

Journal Articles

Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Bárbara Tazón, Laura Gallur, Silvia Saumell, Tamara Jimenez, Teresa Ezponda, Maria Julia Montoro, Félix López Cadenas, Lídia Altimiras, Carla Sánchez Ruiz, Ana Alfonso, Olga Salamero, Ana Pérez, Soraya Peralta, Maria Diez-Campelo, Felipe Prosper, Francesc Bosch, David Valcarcel

Blood (2021) 138 (Supplement 1): 4650.

DOI: https://doi.org/10.1182/blood-2021-150104

Published: 2021

Journal Articles

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A. Sekeres, Larisa Girshova, Vadim A Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Douglas V. Faller, Lionel Ades

Blood (2021) 138 (Supplement 1): 242.

DOI: https://doi.org/10.1182/blood-2021-146154

Published: 2021

Journal Articles

Germline and Somatic Variants Co-Ocurrence Profile in Early Onset Adult Myelodysplastic Syndromes without a Preexisting Disorder

Blood (2021) 138 (Supplement 1): 2595.

DOI: https://doi.org/10.1182/blood-2021-152128

Published: 2021

Journal Articles

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Blood (2021) 138 (Supplement 1): 2610.

DOI: https://doi.org/10.1182/blood-2021-152678

Published: 2021

Journal Articles

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

María Diez-Campelo, Luis E. Benlloch, Emma Sasse, David Wormser, Leyla Hernandez Donoso, Silvia Colicino, Teresa Bernal, Antonieta Molero Yordi, Mar Tormo, Montserrat Arnan Sangerman, Guillermo Sanz, Marina Díaz-Beyá, María Teresa Cedena Romero, Andres Jerez, Brayan Merchán, David Valcárcel

Blood (2021) 138 (Supplement 1): 2605.

DOI: https://doi.org/10.1182/blood-2021-146019

Published: 2021

Journal Articles

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 2606.

DOI: https://doi.org/10.1182/blood-2021-146987

Published: 2021

Journal Articles

Single-Cell Transcriptomics Study of Human Hematopoietic Progenitors Reveals Alterations Associated with Aging and Myeloid Malignancies

Blood (2021) 138 (Supplement 1): 1082.

DOI: https://doi.org/10.1182/blood-2021-153550

Published: 2021

Journal Articles

Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial

Koichi Takahashi, Anna Jonasova, Selina M. Luger, Aref Al-Kali, David Valcarcel, Erica D. Warlick, Maria Diez-Campelo, Michael K Keng, Feng Wang, Ken Furudate, Patrick S. Zbyszewski, Matthew Parris, Steven M. Fruchtman, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 1517.

DOI: https://doi.org/10.1182/blood-2021-152048

Published: 2021

Journal Articles

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

Blood (2021) 138 (16): 1429–1440.

DOI: https://doi.org/10.1182/blood.2021011719

Published: 2021

Includes: Supplemental data

Journal Articles

Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

M Moraima Jimenez, MD, Sabela Bobillo, MD, Ana Pérez, Pamela Arenas, Alba Cabirta, Eva Catala, MD, Yva Rodriguez, MD, Lucia Martin, MD, Angel Serna, MD, Francesc Bosch, MD PhD, David Valcárcel, MD PhD

Blood (2020) 136 (Supplement 1): 14–16.

DOI: https://doi.org/10.1182/blood-2020-142987

Published: 2020

Journal Articles

Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry

Blood (2020) 136 (Supplement 1): 20–21.

DOI: https://doi.org/10.1182/blood-2020-136627

Published: 2020

Journal Articles

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Gloria Iacoboni, MD, Marc Simo, MD, Guillermo Villacampa, Eva Catala, Cecilia Carpio, MD, Candido Diaz-Lagares, MD, Angela Vidal-Jordana, MD, Sabela Bobillo, MD, Ana Marin-Niebla, MD PhD, Ana Perez, MD, Moraima Jiménez, Pau Abrisqueta, MD PhD, David Valcárcel, MD PhD, Francesc Bosch, MD PhD, Pere Barba, MD PhD

Blood (2020) 136 (Supplement 1): 27–29.

DOI: https://doi.org/10.1182/blood-2020-141777

Published: 2020

Journal Articles

Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project)

Blood (2020) 136 (Supplement 1): 32–33.

DOI: https://doi.org/10.1182/blood-2020-139160

Published: 2020

Journal Articles

A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories

Blood (2020) 136 (Supplement 1): 9–10.

DOI: https://doi.org/10.1182/blood-2020-136197

Published: 2020

Journal Articles

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain

Alba Cabirta, Macarena Izuzquiza, MD, Isabel Ruiz-Camps, MD PhD, David Valcarcel, MD PhD, Eva Catala, MD, M Moraima Jimenez, MD, Ana Perez, MD, Lucia Martin, MD, Yva Rodriguez, MD, Angel Serna, MD, Fiorella Ruiz-Pace, Rodrigo Dienstmann, Sabela Bobillo, MD, Cecilia Carpio, MD, Olga Salamero, MD, Pau Abrisqueta, MD PhD, Francesc Bosch, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

DOI: https://doi.org/10.1182/blood-2020-141991

Published: 2020

Journal Articles

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-137789

Published: 2020

Journal Articles

Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival

Blood (2020) 136 (Supplement 1): 13–14.

DOI: https://doi.org/10.1182/blood-2020-140680

Published: 2020

Journal Articles

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Blood (2019) 134 (Supplement_1): 2361.

DOI: https://doi.org/10.1182/blood-2019-122237

Published: 2019

Journal Articles

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Blood (2019) 134 (Supplement_1): 2370.

DOI: https://doi.org/10.1182/blood-2019-125580

Published: 2019

Journal Articles

Transcriptional Regulation of Hematopoietic Stem Cells in Aging and Myelodysplastic Syndrome Reveals DDIT3 As a Potential Driver of Transformation

Blood (2019) 134 (Supplement_1): 3764.

DOI: https://doi.org/10.1182/blood-2019-122686

Published: 2019

2 3 4

NARROW

Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Germline and Somatic Variants Co-Ocurrence Profile in Early Onset Adult Myelodysplastic Syndromes without a Preexisting Disorder

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Single-Cell Transcriptomics Study of Human Hematopoietic Progenitors Reveals Alterations Associated with Aging and Myeloid Malignancies

Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project)

A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Transcriptional Regulation of Hematopoietic Stem Cells in Aging and Myelodysplastic Syndrome Reveals DDIT3 As a Potential Driver of Transformation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only